Abstract

The lymphatic vasculature is involved in the pathogenesis of acute cardiac injuries, but little is known about its role in chronic cardiac dysfunction. Here, we demonstrate that angiotensin II infusion induced cardiac inflammation and fibrosis at 1 week and caused cardiac dysfunction and impaired lymphatic transport at 6 weeks in mice, while co-administration of VEGFCc156s improved these parameters. To identify novel mechanisms underlying this protection, RNA sequencing analysis in distinct cell populations revealed that VEGFCc156s specifically modulated angiotensin II-induced inflammatory responses in cardiac and peripheral lymphatic endothelial cells. Furthermore, telemetry studies showed that while angiotensin II increased blood pressure acutely in all animals, VEGFCc156s-treated animals displayed a delayed systemic reduction in blood pressure independent of alterations in angiotensin II-mediated aortic stiffness. Overall, these results demonstrate that VEGFCc156s had a multifaceted therapeutic effect to prevent angiotensin II-induced cardiac dysfunction by improving cardiac lymphatic function, alleviating fibrosis and inflammation, and ameliorating hypertension.

Data availability

RNA-Seq data has been deposited in GEO under accession code GSE150041. All other data generated during the study are included in the manuscript and supporting files. Source data has been provided for Figure 1-7.

The following data sets were generated

Article and author information

Author details

  1. LouJin Song

    Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States
    Competing interests
    LouJin Song, is an employee at Pfizer inc.
  2. Xian Chen

    Comparative Medicine, Pfizer Inc, Cambridge, United States
    Competing interests
    Xian Chen, is an employee at Pfizer inc.
  3. Terri A Swanson

    Early Clinical Development, Pfizer Inc, Cambridge, United States
    Competing interests
    Terri A Swanson, is an employee at Pfizer inc.
  4. Brianna LaViolette

    Comparative Medicine, Pfizer Inc, Cambridge, United States
    Competing interests
    Brianna LaViolette, is an employee at Pfizer inc.
  5. Jincheng Pang

    Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States
    Competing interests
    Jincheng Pang, is an employee at Pfizer inc.
  6. Teresa Cunio

    Acceleron Pharma, Cambridge, United States
    Competing interests
    Teresa Cunio, was an employee at Pfizer inc and is currently an employee at Acceleron Pharma.
  7. Michael W Nagle

    Eisai Inc, Cambridge, United States
    Competing interests
    Michael W Nagle, was an employee at Pfizer Inc. and is currently an employee at Eisai Inc.
  8. Shoh Asano

    Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States
    Competing interests
    Shoh Asano, is an employee at Pfizer Inc.
  9. Katherine Hales

    Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States
    Competing interests
    Katherine Hales, is an employee at Pfizer Inc.
  10. Arun Shipstone

    Inflammation and Immunology, Pfizer Inc, Cambridge, United States
    Competing interests
    Arun Shipstone, is an employee at Pfizer Inc.
  11. Hanna Sobon

    Inflammation and Immunology, Pfizer Inc, Cambridge, United States
    Competing interests
    Hanna Sobon, is an employee at Pfizer Inc.
  12. Sabra D Al-Harthy

    Comparative Medicine, Pfizer Inc, Cambridge, United States
    Competing interests
    Sabra D Al-Harthy, is an employee at Pfizer Inc.
  13. Youngwook Ahn

    Emerging Science and Innovation, Pfizer Inc, Cambridge, United States
    Competing interests
    Youngwook Ahn, is an employee at Pfizer Inc.
  14. Steven Kreuser

    Comparative Medicine, Pfizer Inc, Cambridge, United States
    Competing interests
    Steven Kreuser, is an employee at Pfizer Inc.
  15. Andrew Robertson

    Drug Safety Research & Development, Pfizer Inc, Cambridge, United States
    Competing interests
    Andrew Robertson, is an employee at Pfizer Inc.
  16. Casey Ritenour

    Drug Safety Research & Development, Pfizer Inc, Cambridge, United States
    Competing interests
    Casey Ritenour, is an employee at Pfizer Inc.
  17. Frank Voigt

    Drug Safety Research & Development, Pfizer Inc, Cambridge, United States
    Competing interests
    Frank Voigt, is an employee at Pfizer Inc.
  18. Magalie Boucher

    Drug Safety Research & Development, Pfizer Inc, Cambridge, United States
    Competing interests
    Magalie Boucher, is an employee at Pfizer Inc.
  19. Furong Sun

    Early Clinical Development, Pfizer Inc, Cambridge, United States
    Competing interests
    Furong Sun, is an employee at Pfizer Inc.
  20. William C Sessa

    Pharmacology, Yale School of Medicine, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5759-1938
  21. Rachel J Roth Flach

    Internal Medicine Research Unit, Pfizer Inc, Cambridge, United States
    For correspondence
    Rachel.RothFlach@pfizer.com
    Competing interests
    Rachel J Roth Flach, is an employee at Pfizer Inc.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2754-828X

Funding

Pfizer

  • Rachel J Roth Flach

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The ethics statement has been included in the method section of the manuscript as the following:"All animal experimental procedures were carried out in accordance with regulations and established guidelines and were reviewed and approved by the Pfizer Institutional Animal Care and Use Committee(AUP # KSQ-2013-00895)."

Copyright

© 2020, Song et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,730
    views
  • 330
    downloads
  • 39
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. LouJin Song
  2. Xian Chen
  3. Terri A Swanson
  4. Brianna LaViolette
  5. Jincheng Pang
  6. Teresa Cunio
  7. Michael W Nagle
  8. Shoh Asano
  9. Katherine Hales
  10. Arun Shipstone
  11. Hanna Sobon
  12. Sabra D Al-Harthy
  13. Youngwook Ahn
  14. Steven Kreuser
  15. Andrew Robertson
  16. Casey Ritenour
  17. Frank Voigt
  18. Magalie Boucher
  19. Furong Sun
  20. William C Sessa
  21. Rachel J Roth Flach
(2020)
Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension
eLife 9:e58376.
https://doi.org/10.7554/eLife.58376

Share this article

https://doi.org/10.7554/eLife.58376

Further reading

    1. Cell Biology
    Dharmendra Kumar Nath, Subash Dhakal, Youngseok Lee
    Research Advance

    Understanding how the brain controls nutrient storage is pivotal. Transient receptor potential (TRP) channels are conserved from insects to humans. They serve in detecting environmental shifts and in acting as internal sensors. Previously, we demonstrated the role of TRPγ in nutrient-sensing behavior (Dhakal et al., 2022). Here, we found that a TRPγ mutant exhibited in Drosophila melanogaster is required for maintaining normal lipid and protein levels. In animals, lipogenesis and lipolysis control lipid levels in response to food availability. Lipids are mostly stored as triacylglycerol in the fat bodies (FBs) of D. melanogaster. Interestingly, trpγ deficient mutants exhibited elevated TAG levels and our genetic data indicated that Dh44 neurons are indispensable for normal lipid storage but not protein storage. The trpγ mutants also exhibited reduced starvation resistance, which was attributed to insufficient lipolysis in the FBs. This could be mitigated by administering lipase or metformin orally, indicating a potential treatment pathway. Gene expression analysis indicated that trpγ knockout downregulated brummer, a key lipolytic gene, resulting in chronic lipolytic deficits in the gut and other fat tissues. The study also highlighted the role of specific proteins, including neuropeptide DH44 and its receptor DH44R2 in lipid regulation. Our findings provide insight into the broader question of how the brain and gut regulate nutrient storage.

    1. Cell Biology
    2. Immunology and Inflammation
    Mykhailo Vladymyrov, Luca Marchetti ... Britta Engelhardt
    Tools and Resources

    The endothelial blood-brain barrier (BBB) strictly controls immune cell trafficking into the central nervous system (CNS). In neuroinflammatory diseases such as multiple sclerosis, this tight control is, however, disturbed, leading to immune cell infiltration into the CNS. The development of in vitro models of the BBB combined with microfluidic devices has advanced our understanding of the cellular and molecular mechanisms mediating the multistep T-cell extravasation across the BBB. A major bottleneck of these in vitro studies is the absence of a robust and automated pipeline suitable for analyzing and quantifying the sequential interaction steps of different immune cell subsets with the BBB under physiological flow in vitro. Here, we present the under-flow migration tracker (UFMTrack) framework for studying immune cell interactions with endothelial monolayers under physiological flow. We then showcase a pipeline built based on it to study the entire multistep extravasation cascade of immune cells across brain microvascular endothelial cells under physiological flow in vitro. UFMTrack achieves 90% track reconstruction efficiency and allows for scaling due to the reduction of the analysis cost and by eliminating experimenter bias. This allowed for an in-depth analysis of all behavioral regimes involved in the multistep immune cell extravasation cascade. The study summarizes how UFMTrack can be employed to delineate the interactions of CD4+ and CD8+ T cells with the BBB under physiological flow. We also demonstrate its applicability to the other BBB models, showcasing broader applicability of the developed framework to a range of immune cell-endothelial monolayer interaction studies. The UFMTrack framework along with the generated datasets is publicly available in the corresponding repositories.